- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02410135
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Illinois
-
Springfield, Illinois, United States, 62794-9665
- SIUSOM - Division of Urology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18.
- Subject is willing and able to complete the micturition diary and sleep questionnaires correctly.
- Symptoms of overactive bladder (OAB) (urinary frequency and urgency with or without urgency incontinence) for at least 3 months, with an IPSS ≥ 12.
- Moderate sleep disturbance with a mean score on the Jenkins Scale > 7.
- Micturitions/24 hrs ≥ 8; total excretory volume of <3L.
- Washout period of 2 weeks for any drugs not listed in the exclusions.
Exclusion Criteria:
Subject is using prohibited medications which cannot be stopped safely at the screening visit. Subject is excluded if using restricted medications not meeting protocol-specified criteria:
(i) Phytotherapy for benign prostatic hypertrophy (BPH) or a 5-alpha reductase inhibitor within 3 months.
(ii) Alpha blocker within 2 weeks. (iii) Taken an oral alpha agonist, tricyclic antidepressants, and anticholinergic or cholinergic medication within 2 weeks of the first screening visit with the following exception: topical anticholinergic eye drops used for glaucoma or inhaled anti-cholinergic used for chronic obstructive pulmonary disease (COPD).
(iv) Taken an estrogen, androgen, or any drug producing androgen suppression, or anabolic steroids within 3 months.
- Post void residual volume > 350 mL.
- Female subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential is sexually active and not practicing a highly reliable method of birth control.
- Subject has neurogenic bladder.
- Any prior invasive intervention for LUTS (including bladder paralytics such as botulin toxin)
- Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator (for female subjects confirmed by a cough provocation test).
- Subject has an indwelling catheter or practices intermittent self-catheterization.
- Known primary neurologic conditions such as multiple sclerosis, Parkinson's disease, diabetic neuropathy or any neurological diseases known to affect bladder function.
- Subject has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs.
- Two documented independent urinary tract infections of any type in the past year.
- Patient with a diagnosed sleep disorder (ie. Obstructive Sleep Apnea) undergoing evaluation and treatment requiring change in care within 30 days of screening visit.
- Subject has moderate to severe hepatic impairment [ALT (SGPT), AST (SGOT) or GGT value greater than 3 times the upper limit of normal in the clinical center lab; confirmed on a second measurement].
- Subject has severe renal impairment or End Stage Renal disease (i.e., creatinine greater than 2.0 mg/dl).
- PSA (prostate specific antigen) level greater than 10 ng/ml at the first screening visit (if male).
- Subject has severe uncontrolled hypertensionas defined by a systolic pressure ≥180 mmHg and/or diastolic pressure ≥120 mmHg.
- Subject has a clinically significant abnormal ECG or has a known history of QT prolongation or currently taking medication known to prolong the QT interval.
- Subject has a known or suspected hypersensitivity to Mirabegron or any of the inactive ingredients.
- Subject has a concurrent malignancy or history of cancer (except noninvasive skin cancer) within the last 5 years prior to screening. Men with a history of prostate cancer regardless of curability are not eligible.
- Subject has been treated with an experimental device within 30 days or received an experimental agent within the longer of 30 days or five half-lives.
- Unable to follow protocol directions due to organic brain or psychiatric disease.
- History of alcoholism or any other substance abuse, which, in the opinion of the investigator, would affect compliance with the protocol.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with symptomatic LUTS and disordered sleep
Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
|
25 mg PO per day for four weeks.
if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Improvement from baseline on the PROMIS Sleep Disturbance scale at the 12 week follow-up.
Time Frame: 12 weeks
|
12 weeks
|
• Improvement from baseline in the number micturitions/24 hours at the 12 week follow-up.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Improvement from baseline on the Jenkins sleep scale at the 12 week follow-up.
Time Frame: 12 weeks
|
12 weeks
|
• Improvement of nocturia (nocturnal voiding) based on the amount of voids that disrupt patient sleep in the voiding diary.
Time Frame: 12 weeks
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Improvement from baseline on the International Prostate Symptom Score (IPSS)/American Urological Society Symptom Index (AUA-SI) scale at the 12 week follow-up.
Time Frame: at 12 week follow-up
|
exploratory endpoint
|
at 12 week follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin McVary, MD, Southern Illinois University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MYRB-14B03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Urinary Tract Symptoms
-
The Royal College of Surgeons of EnglandUniversity College, LondonCompletedUncomplicated Lower Urinary Tract Symptoms
-
National Taiwan University HospitalUnknownDisorder of the Lower Urinary TractTaiwan
-
ProVerum MedicalNot yet recruitingBPH With Symptomatic Lower Urinary Tract Symptoms
-
The University of Texas Medical Branch, GalvestonCompletedLower Urinary Tract Symptoms | Lower Gastrointestinal Tract Symptoms
-
Far Eastern Memorial HospitalCompletedPsychiatric Aspects in Women With Lower Urinary Tract SymptomsTaiwan
-
Baylor Research InstituteForte MedicalCompletedLower Urinary Tract Symptoms | Lower Urinary Tract InfectionUnited States
-
Jagiellonian UniversityPiotr ChlostaCompletedTo Evaluate Lower Urinary Tract Symptoms (LUTS) in PolandPoland
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterUnknownPain | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States
-
San Carlo di Nancy HospitalLampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy)CompletedBPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsItaly
Clinical Trials on Mirabegron
-
The Affiliated Ganzhou Hospital of Nanchang UniversityActive, not recruiting
-
Astellas Pharma IncCompletedHealthy Subjects | Plasma Concentration of MirabegronJapan
-
Thomas Jefferson UniversityAstellas Pharma IncTerminatedAchalasiaUnited States
-
Astellas Pharma IncCompletedHealthy Subjects | Bioavailability | Pharmacokinetics of MirabegronNetherlands
-
Cedars-Sinai Medical CenterRecruitingSyncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic IntoleranceUnited States
-
Far Eastern Memorial HospitalRecruitingOveractive Bladder SyndromeTaiwan
-
Far Eastern Memorial HospitalRecruitingFemale Patients With Overactive Bladder SyndromeTaiwan
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Urinary Bladder Diseases | Urinary Bladder OveractiveUnited States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
-
Peking Union Medical College HospitalNot yet recruiting
-
Astellas Pharma Europe B.V.Completed